How Irun Cohen and Weizmann Institute almost cured diabetes

How Irun Cohen and Weizmann Institute almost cured diabetes

This is a new episode of the data manipulation affair around Weizmann Institute of Science in Rehovot, Israel (and another guest post by “Smut Clyde“), with the hope that Israeli researchers and their state officials finally step in and investigate what goes on in this institute, supported by external experts from the academic community. There are many good and honest researchers working at Weizmann, the dishonest deeds which used to happen (and maybe still happen at Weizmann) should never throw a shadow upon their work. This can only be achieved by an open debate in the scientific community worldwide and a large, independent investigation inside Weizmann.

My earlier article about Weizmann’s “stars” of research integrity, and the follow-up guest post by Smut Clyde, prompted a wider scrutiny by internet sleuths on PubPeer. One of them was the well-known pseudonymous Claire Francis. In this case presented below, while Ofer Lider, associate professor of Immunology at Weizmann, was dying from leukaemia, his dedicated colleagues were apparently secretly stuffing manipulated data into his publications. They continued to do so even after his death in 2004, and now Lider papers are being plucked apart on PubPeer. There are many co-authors, and the scientific narrative mostly circles around a “visionary” diabetes cure, the substance DiaPep277, a peptide fragment of the ubiquitous heatshock protein Hsp60.

What was done to the scientific and human legacy of the immunologist Ofer Lider, is the basically academic equivalent of urinating of someone’s literal grave. If this won’t make Weizmann leadership feel shame, I do not know what would. It was a travesty of two retracted papers and a meeting abstract of a DiaPep277 clinical trial by the trainwreck company Andromeda Biotech, and it made world news in 2014. What came out only now, thanks to the sleuths of PubPeer, is that this scandal of clinical trial statistics was supported by a preclinical cornucopia of rigged western blots made at Weizmann, which all served the purpose of delivering a promise of a diabetes “vaccine”.

Continue reading “How Irun Cohen and Weizmann Institute almost cured diabetes”

Jungebluth injunction hearing, another court travesty

Yesterday, November 23rd 2017, I travelled 600 km to Berlin to stand my second injunction trial, instigated by Philipp Jungebluth, former student and acolyte of the scandal surgeon. The first injunction was achieved by Jungebluth based on his claim to be world-famous, renowned researcher and clinician, who helped save the lives of patients like Andemariam Beyene and Hannah Warren with plastic tracheas and published about this in The Lancet (a paper which is now up for retraction due to his and Macchiarini’s proven misconduct). The second injunction was pushed against my article about an unpublished manuscript of Macchiarini’s and Jungebluth’s, from which I have quoted and interpreted with reference to the quotes. That injunction was founded now on the opposite: Jungebluth denies to have had anything at all to do with any of Macchiarini’s trachea transplants, aside of a very general academic, but never ever any clinical, contribution.

The hearing yesterday was a proper farce. It began with the judge asking Jungebluth’s lawyer why he didn’t forbid me to say his client had anything at all to do with Claudia Castillo’s transplant as well (read more here, also about Jungebluth’s role). The court and indicated it would be more than happy to oblige Jungebluth and his lawyer if they were interested. Soon it became rather obvious that the main judge and his two colleagues have never read my English-language article before passing the injunction against it, that they are more confident in their knowledge of English language than they should be, and that they have no understanding whatsoever on the practices of how a biomedical research paper is written. Yet they believe that their power position allows them to make such decisions and disperse punishments nevertheless.

The main issue was the authors’ contributions statement “P.J. assisted in clinical transplantations and preclinical experiments and helped to write the report” which went with the unpublished manuscript describing 9 cadaveric trachea transplants in human patients and some rat experiments. Jungebluth and his lawyer never denied the existence of that manuscript or my quotes from it. But now guess how the judges understood the statement “P.J. assisted in clinical transplantations“?

Continue reading “Jungebluth injunction hearing, another court travesty”

Tissue-engineered tracheas: an assessment of the scientific, clinical and ethical implications

Tissue-engineered tracheas: an assessment of the scientific, clinical and ethical implications

Here I republish the written evidence submitted to by two UK scientists to the Science and Technology Committee of the British House of Commons and its inquiry into Research Integrity, as originally published on November 21st 2017. It deals with the trachea transplants performed by the surgeons Paolo Macchiarini and his former parter at UCL, Martin Birchall. The report’s lead author is Patricia Murray, professor in stem cell biology and regenerative medicine, previously a nurse on a Head and Neck unit. She generously invited me in May 2017 to give a seminar at her department at the University of Liverpool on this topic. Her coauthor is Raphael Lévy, senior lecturer in nanotechnology and imaging at the same university. I wrote about his reproducibility studies on the topic of nanoparticles in this article.

800ABE38-9C0C-4E6A-A0A6-014E8827B9E3 Trish
Prof. Patricia Murray

UCL recently investigated Birchall’s past trachea transplants, and recommended to continue with his two current clinical trials to transplant cadaveric decellurised trachea and larynx, regenerated with bone marrow cells, as I reported here. For some reason, UCL Registrar Wendy Appleby, when speaking as witness on November 21st in front of the Parliament Inqury, found herself unable to answer the rather straightforward question whether the UCL investigative commission advised to continue transplanting trachea or not (watch here, from 11:50 on). Appleby and her UCL were instructed by the Inquiry to address the concerns by Murray and Levy in writing.

Both clinical trials  Inspire and RegenVox were already placed by the supervising authorities on hold, Murray and Levy now call to stop the dangerous and science-unsupported experimenting on misinformed human patients and to return back to the lab.

Following is a copy of the (originally published on the UK Parliament website), Continue reading “Tissue-engineered tracheas: an assessment of the scientific, clinical and ethical implications”

Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out

Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out

My earlier article presented the worrisome research integrity record at the gigantic US cancer research hospital MD Anderson Cancer Center, part of the University of Texas in Houston. Its particular focus was the ovarian cancer researcher Anil Sood, professor of Gynecologic Oncology and Reproductive Medicine and co-director of Center for RNA Interference and Non-Coding RNAs at MD Anderson. Meanwhile I have been contacted by no less than 4 former Sood associates with their concerns, because they say MD Anderson does not take them seriously. A pseudonymous guest post by one of these whistleblowers, together with some evidence, is published below.

Sood’s record of appalling duplications of microscopy image and western blot bands in his papers is evident on PubPeer, no less than 40 papers are flagged, spanning so far a period from 2004 until now. The whistleblowers who contacted me now also accuse Sood of inappropriate data handling, since he was apparently removing or adjusting data points on a whim, and taught his lab members to do the same. The results based on this creatively acquired mouse experiment data as well as duplicated images served to initiate at MD Anderson a clinical trial with up to 90 “patients with histologic proof of advanced solid tumors ” to test a siRNA based therapy, this trial is lead by Sood’s associate Robert Coleman, who is professor at the same department.

Worst of all: MD Anderson doesn’t care about what happens in Sood’s lab. They do have guidelines for research integrity, printable as pdf, but those seem to serve as a kind of toilet paper to wipe professorial bums with. As a whistleblower informed me, nine researchers working on different projects in Sood’s lab complained to Office of Research Integrity (ORI) or MD Anderson’s own Research Integrity Officer (RIO) William Plunkett or Department Chairs or Ombuds Office or Dean of Graduate School, Michelle Barton, since August 2016. In fact, those who complained where told to find another job, or were dealt otherwise with. There never was any investigation, only “leak of confidentiality”, while the University of Texas graduate school keeps sending fresh students to learn at Sood’s lab. Meanwhile, as a whistleblower wrote: “Most Sood core members already escaped, and got a job thanks to their publication with suspected allegations“.

Continue reading “Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out”

Martin Birchall’s shaky road to mass trachea transplanting

Martin Birchall’s shaky road to mass trachea transplanting

The British laryngologist and UCL professor Martin Birchall is one of the two founding fathers of “bioengineered” trachea, the other one being his former partner, the scandal surgeon Paolo Macchiarini. Birchall presently runs three trachea transplant trials clinical trials, two in the UK and one EU-wide. His patients must however wait to be cured, because the two UK trials, Inspire and RegenVox (with the latter primarily about larynx and upper trachea transplant) were both placed on hold, and the EU funded phase 2 trial TETRA is still far from getting an ethics approval and just now lost one potential trial site after the Medical University Vienna jumped ship. The EU Commission refuses to tell me anything about TETRA, except that it has not applied for ethics approval yet. EU’s Transparence department still evade commenting on how to put this scheduled 48 patient clinical trial in context of the 11 cadaveric trachea transplants by Macchiarini and Birchall, most or maybe even all of which left the patients either dead or mutilated.

In this article, I publish the most recent patient information sheets for the two suspended Inspire and RegenVox trachea transplant clinical trials, which I obtained under Freedom of Information request from the UK Health Research Authority (HRA).  Continue reading “Martin Birchall’s shaky road to mass trachea transplanting”

Call to research integrity, or at least a minor revolution at CNRS

Call to research integrity, or at least a minor revolution at CNRS

When I first started digging into the affair of data manipulations around the former star of plant sciences Olivier Voinnet in early 2015, I was sure to be dealing with a singular case of fraud in French science, which went totally unnoticed for decades. When 2 years later I wrote “a fish stinks from the head down” in my article about Voinnet’s former Strasbourg plant sciences institute and its problematic director, I did not know how far up to the very top this data manipulation scandal will go. Now, it looks like the entire leadership of  the Centre National de la Recherche Scientifique (CNRS), French state’s own network of research institutes, might be corrupted and rotten. Research and its integrity at this “largest fundamental research organization in Europe” are overseen by the very people whose own publications should be under investigation for suspected misconduct. A minor revolution is in order in French science, for which I would like to make a case here.

The new interim president of the entire CNRS of 32,000 research employees with the annual budget of €3.2 Billion, Anne Peyroche, has seen now her own publications flagged on PubPeer for data irregularities. In fact, PubPeer itself, which is run by two CNRS employees, seems to be in a pickle. They now vigorously police and delete attempts of criticisms of Peyroche papers. Is the whistleblowing site fighting for its survival, afraid that CNRS might impose its demise any time? How far is the CNRS’ leadership prepared to go, now that their power is threatened by the evidence of misconduct in their own papers?

Catherine Jessus, being the director of its l’Institut des sciences biologiques (INSB) basically the head biologist at CNRS, already reacted to a stream of evidence against her publications on my site and on PubPeer. No, she is apparently not going to check lab books or provide for original data. Instead she declared to her colleagues that CNRS will soon start a massive legal action against yours truly. If true, the State of France announced to soon set its power and resources upon a German blogger, yet the French media refuses to report anything until CNRS issues an official statement in this regard. This information I have from direct sources.

Continue reading “Call to research integrity, or at least a minor revolution at CNRS”

Human Brain Project interview with Thomas Lippert: Simulating brain in computer is like simulating weather

Human Brain Project interview with Thomas Lippert: Simulating brain in computer is like simulating weather

Following is my email interview with Thomas Lippert, professor and director of the Institute for Advanced Simulation and the Jülich Supercomputing Centre at the Forschungszentrum Jülich in the west of Germany, located somewhere between the cities of Cologne and Aachen. Lippert’s FZ Jülich is a central partner at the Human Brain Project (HBP), the Future and Emerging Technologies (FET) Flagship mega-consortium which is funded with €1 Billion, half of which coming from the European Union.  Lippert heads the Subproject (SP) 7 at the HBP, named High-Performance Analytics and Computing Platform, tasked with providing the high-performance computational power in order to help the HBP megaproject simulate the human brain and its diseases.

I previously wrote some critical articles about HBP, about the hubris of its founding father Henry Markram, the bizarre way EU positively evaluated the performance of HBP without actually evaluating it, and also about the purpose of HBP and Flagship projects in general. Incidentally, the last article’s cover photo showed Lippert at a HBP conference. We got into a discussion over Twitter during HBP’s recent Open Day show in Glasgow, where Lippert kindly agreed to answer my questions about the purpose and orientation of HBP.

Continue reading “Human Brain Project interview with Thomas Lippert: Simulating brain in computer is like simulating weather”